Bottom Line Booster

Given the colossal revenue generated by just one blockbuster drug, it's no surprise that R&D always finds its way to the top of management's agenda. But now more than ever, pharmaceutical companies can't thrive on discovery alone. Price pressure from the public and private sectors drives companies to create savings through operational efficiencies. One of the biggest areas for financial gain"better management of capital assets"is often overlooked.

Related Content:

Pharmaceutical Executive-07-01-2001

Amgen's New Dream Team

Pharmacies: OTC Price Wars

One Disease at a Time